Time filter

Source Type

Gasteiz / Vitoria, Spain

Diaz-Ley B.,Hospital Ramon y Cajal | Cuevast J.,Hospital Universitario Of Guadalajara | Alonso-Castro L.,Hospital Ramon y Cajal | Calvo M.I.,Research Foundation | And 3 more authors.
Dermatologic Therapy | Year: 2015

Skin ageing is characterized by small and fine wrinkles, roughness, laxity, and pigmentation as a result of epidermal thinning, collagen degradation, dermal atrophy, and fewer fibroblasts. Plasma rich in growth factors (PRGF) is an autologous plasma preparation enriched in proteins obtained from patient's own blood aimed at accelerating tissue repair and regeneration. To evaluate the benefits of PRGF in skin photodamage, 10 healthy volunteers were treated with three consecutive intradermal injections of PRGF in the facial area. Clinical outcomes and histological analysis were performed. A statistically significant increase in the epidermis and papillary dermis thickness was seen after PRGF treatment (p < 0.001). Skin thickening was observed in all patients studied, being more intense in the group of patients with photodamage (p < 0.001). After PRGF treatment, a reduction of the average area fraction of solar elastosis was observed in patients with clinical and histological signs of skin photodamage (p < 0.05).No changeswere observed in the number of CD31, XIIIa factor, cKit, CD10, nor p53-positive cells. The improvement score after PRGF use was 0.75 (9/12) for the group of patients with signs of skin photodamage. Intradermal PRGF infiltration appears to be an effective treatment for the photodamaged skin. © 2015 Wiley Periodicals, Inc. Source

Anitua E.,Implantology and Oral Rehabilitation | Anitua E.,BTI Biotechnology Institute | Tejero R.,BTI Biotechnology Institute | Alkhraisat M.H.,BTI Biotechnology Institute | And 4 more authors.
BioDrugs | Year: 2013

Growth factors and cytokines are active players in controlling the different stages of wound healing and tissue regeneration. Recent trends in personalized regenerative medicine involve using patient's own platelet-rich plasma for stimulating wound healing and tissue regeneration. This technology provides a complex cocktail of growth factors and even a fibrin scaffold with multiple biologic effects. In the last few years, an increasing number of studies provide evidence of the potential of combining platelet-rich plasma with different biomaterials in order to improve their properties, including handling, administration, bioactivity, and level of osseointegration, among others. In this review, we discuss the use of platelet-rich plasma as an alternative, easy, cost-effective, and controllable strategy for the release of high concentrations of many endogenous growth factors. Additionally, we provide an overview of the current progress and future directions of research combining different types of biomaterials with platelet-rich plasma in tissue engineering and regenerative medicine. © 2012 Springer International Publishing Switzerland. Source

Anitua E.,Eduardo Anitua Foundation | Anitua E.,BTI Biotechnology Institute | Zalduendo M.M.,BTI Biotechnology Institute | Alkhraisat M.H.,BTI Biotechnology Institute | Orive G.,BTI Biotechnology Institute
Annals of Anatomy | Year: 2013

Many studies have evaluated the biological effects of platelet rich plasma reporting the final outcomes on cell and tissues. However, few studies have dealt with the kinetics of growth factor delivery by plasma rich in growth factors. Venous blood was obtained from three healthy volunteers and processed with PRGF-Endoret technology to prepare autologous plasma rich in growth factors. The gel-like fibrin scaffolds were then incubated in triplicate, in a cell culture medium to monitor the release of PDGF-AB, VEGF, HGF and IGF-I during 8 days of incubation. A leukocyte-platelet rich plasma was prepared employing the same technology and the concentrations of growth factors and interleukin-1β were determined after 24. h of incubation. After each period, the medium was collected, fibrin clot was destroyed and the supernatants were stored at -80. °C until analysis. The growth factor delivery is diffusion controlled with a rapid initial release by 30% of the bioactive content after 1. h of incubation and a steady state release when almost 70% of the growth factor content has been delivered. Autologous fibrin matrix retained almost 30% of the amount of the growth factors after 8 days of incubation. The addition of leukocytes to the formula of platelet rich plasma did not increase the concentration of the growth factors, while it drastically increased the presence of pro-inflammatory IL-1β. Further studies employing an in vitro inflammatory model would be interesting to study the difference in growth factors and pro-inflammatory cytokines between leukocyte-free and leukocyte-rich platelet rich plasma. © 2013 Elsevier GmbH. Source

Anitua E.,BTI Biotechnology Institute | Prado R.,BTI Biotechnology Institute | Orive G.,BTI Biotechnology Institute
Operative Techniques in Orthopaedics | Year: 2012

Platelet-rich plasma is a set of autologous platelet products used to accelerate recovery from injury. The basic rationale is to mimic the natural ways of healing, bringing to the injury site a set of molecules that will accelerate the functional recovery of the tissue, trying to regenerate the tissue itself, and not to merely repair with scar tissue. Among the jungle of products in this field, PRGF-Endoret (BTI-Biotechnology Institute, Vitoria, Spain) is a pioneering autologous regenerative technology with multiple therapeutic potentials, present in at least 4 different formulations, depending on the coagulation and activation degree of the samples. PRGF-Endoret technology is safe and has multiple applications and potentials. © 2012 Elsevier Inc. Source

Anitua E.,BTI Biotechnology Institute | Alkhraisat M.H.,BTI Biotechnology Institute | Miguel-Sanchez A.,University of Murcia | Orive G.,BTI Biotechnology Institute
Journal of Oral and Maxillofacial Surgery | Year: 2014

Purpose To report on the outcomes of a new surgical technique for the treatment of severe horizontal bone resorption that impedes the placement of dental implants. Materials and Methods Eleven patients in need of bone augmentation to reconstruct a narrow alveolar ridge were recruited for the present study. Surgical correction of the alveolar width was performed by harvesting an onlay bone graft from the lateral wall of the maxillary sinus and filling the intervening space with plasma rich in growth factors alone or mixed with autologous bone particles. A fibrin membrane was then placed to cover the surgical site before flap closure. Clinical examinations and cone-beam computed tomography were performed to analyze the safety and efficiency of an onlay bone graft from the maxilla in horizontal bone augmentation. Results The present study is the first to describe the lateral wall of the maxillary sinus as a donor site for an onlay bone graft. The healing period was uneventful, with minimal surgical morbidity. No flap exposure occurred, and analysis of the cone-beam computed tomography scans before and after (about 5 months) bone augmentation revealed a total gain of 5.4 mm in alveolar width. This permitted the placement of dental implants to support an implant-borne prosthesis. Conclusions An onlay bone graft from the lateral wall of the maxillary sinus is a useful and safe tool for horizontal bone augmentation with minimal surgical morbidity. © 2014 American Association of Oral and Maxillofacial Surgeons. Source

Discover hidden collaborations